Trifluoroacetic Acid
Trifluoroacetic acid is a corrosive organofluorine compound that is structurally analogous to, but stronger than, acetic acid. Available in various quantities and reagent grades, it is used in NMR spectroscopy, mass spectrometry, organic synthesis, etc.
Almost 100,000-fold more acidic than acetic acid, TFA is widely used in organic chemistry. TFA is used as a reagent in organic synthesis because of its properties: volatility, organic solvent solubility, and acidic strength. It is less oxidizing than sulfuric acid and is more readily available in its anhydrous form than some other acids . Other features include:
- Used in acid-catalyzed reactions, especially peptide synthesis (to cleave esters)
- Dissolves protein when mixed with liquid SO2
- Removes t-butyl derived side-chain protecting groups in Fmoc peptide synthesis
- Can remove the t-butoxycarbonyl protecting group in organic synthesis
- At low concentrations, acts as an ion-pairing agent for peptides and small proteins in organic compound liquid chromatography
- For acid-stable materials, can be a solvent for NMR spectroscopy
- Acts as a calibrant in mass spectrometry
- Used to produce trifluoroacetate salts
- An ingredient in adhesives, sealants, paints, and coatings
When TFA combines with bases and metals, especially light metals, a strong exothermic reaction occurs. When mixed with lithium aluminum hydride (LAH), the reaction is explosive.
Although nonflammable, TFA is corrosive to skin, eyes, and mucous membranes and requires careful use and handling. It is harmful when inhaled, causes severe skin burns and eye damage, and is toxic to aquatic organisms at even low concentrations.
TFA is also a product of the metabolic breakdown of the anesthetic agent halothane. It is the suspected cause of halothane-induced hepatitis.
Medchemexpress LLC LL-37 amide (TFA) | 99.34% | 4492.28 | 5 MG
LL-37 amide TFA is a selective agonist of formyl peptide receptor-like FPRL1, effectively inhibiting periodontal pathogens. It exerts bactericidal effects by activating immune cell chemotaxis and disrupting bacterial cell membrane integrity. This peptide also regulates inflammatory responses and promotes angiogenesis. Its amidation modification reduces sensitivity to serum inhibition and improves stability, making it suitable for research on infection-related diseases like periodontal disease, deep tissue injuries, and wound healing.
- Selective agonist of formyl peptide receptor-like FPRL1
- Inhibits periodontal pathogens
- Exerts bactericidal effects
- Regulates inflammatory responses
- Promotes angiogenesis
- Improved stability and resistance to enzymatic degradation
- Useful in research for infection-related diseases and wound healing
- Effective against Gram-positive and Gram-negative bacteria
Medchemexpress LLC BIM 23042 (trifluoroacetate) | 00-00-0 | MFCD32666112 | 96.2% | 1192.45 g/mol | C63H73N11O9S2·xC2HF3O2 | 1 MG
BIM 23042 (trifluoroacetate) is a somatostatin-like octapeptide analogue that acts as a selective neuromedin B receptor (NMB-R/BB1) antagonist. It is supplied as the trifluoroacetate salt in solid form for research use in receptor pharmacology and intracellular calcium signaling studies.
- Selective neuromedin B receptor (NMB-R/BB1) antagonist.
- Somatostatin-like octapeptide structure as the trifluoroacetate salt.
- Purity approximately 96.2% by supplier analysis.
- White to off-white solid powder suitable for laboratory use.
- Store sealed away from moisture and light; powder stable at -80°C (2 years) or -20°C (1 year).
Medchemexpress LLC AS-99 TFA | 99.2% | C29H31F6N5O5S2 | 1 ML
AS-99 TFA is a first-in-class, potent, and selective ASH1L histone methyltransferase inhibitor with anti-leukemic activity. It blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo. The compound has an IC50 of 0.79 μM and a Kd of 0.89 μM for ASH1L.
- First-in-class, potent, and selective ASH1L histone methyltransferase inhibitor.
- Exhibits anti-leukemic activity.
- Blocks cell proliferation.
- Induces apoptosis and differentiation.
- Downregulates MLL fusion target genes.
- Reduces leukemia burden in vivo.
- Selective for ASH1L, with no significant inhibition observed at 50 μM on a panel of 20 other histone methyltransferases.
Apexbio Technology LLC cyclo(RLsKDK) TFA(Synonyms: cyclo(RLsKDK), Cyclic peptide RLsKDK, ADAM8 inhibitor peptide, Cyclo-Arg-Leu-Ser-Lys-Asp-Lys), 1mg.
Cyclo(RLsKDK) TFA is a cyclic pentapeptide inhibitor targeting the metalloproteinase ADAM8 a transmembrane protein frequently dysregulated in pathological conditions such as inflammation cancer and neurodegenerative diseases By specifically inhibiting ADAM8 enzymatic activity cyclo(RLsKDK) TFA may modulate disease-associated cellular processes This molecule holds promise as a research tool for studying ADAM8 function and as a potential therapeutic candidate in inflammatory disorders and oncology
